Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$11.65 USD
+0.33 (2.92%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $11.66 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PHAT 11.65 +0.33(2.92%)
Will PHAT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PHAT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Lags Revenue Estimates
Zacks.com featured highlights include Phathom Pharmaceuticals, Universal Stainless & Alloy Products and Arlo Technologies
PHAT: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Top Breakout Stocks Worth a Buy for Attractive Returns
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for PHAT
Optimistic Outlook on Phathom Pharmaceuticals Despite Temporary Prescription Dip
Phathom Pharmaceuticals: Time To Deliver Promise Of Voquezna After Frustrating Delays
Wall Street Breakfast: The Week Ahead
Optimistic Outlook for V oquezna’s Market Penetration and Future Sales Despite Temporary Dip
Catalyst Watch: Nike earnings, Datadog event, Norfolk Southern decision, and an oil field-crypto IPO